Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Explore this paper's citation graph
Summary
It is suggested that bortezomib provides a cost-effective treatment option and the best value (in terms of cost/life-yr gained) among the currently available therapeutic options for relapsed, refractory myeloma.
- Type
- article
- Published
- 2004-09-01
- Cited by
- 29
- References
- 34
- OpenAlex
- https://openalex.org/W10535914
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6735779
Keywords
Bortezomib, Multiple myeloma, Thalidomide, Medicine, Lenalidomide
References
- The cost of chronic dialysis in multiple myeloma.
- Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.
- How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
- Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
- The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.
- Cost‐effectiveness of high‐dose chemotherapy in first‐line treatment of advanced multiple myeloma
- Thalidomide in refractory and relapsing multiple myeloma.
- Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma
- Economic impact of using clodronate in the management of patients with multiple myeloma
- Current therapy for multiple myeloma.
- Treatment of relapsed and refractory multiple myeloma
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
- Resource-based relative values. An overview.
- Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug
- Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
- Costs of intensive treatment and follow-up of patients with multiple myeloma.
- Cost–utility analysis of high‐dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
- Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma
- Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
- Standard treatment of multiple myeloma.
Cited by
- Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
- Economic Evaluations of Targeted Therapy and Risk-Stratified Treatment Approaches in Multiple Myeloma
- Decision making in drug reimbursement
- The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
- An update: health economics of managing multiple myeloma.
- Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.
- Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
- Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
- Bortezomib: the evidence of its clinical impact in multiple myeloma
- Efficient allocation of novel agents in multiple myeloma: a work in progress.
- Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.
- Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
- New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals.
- Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.
- Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
- The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
- Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review.
- Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience
- Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model
- Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
Related papers
- Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
- Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
- Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
- Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy
- Stem cell transplantation for multiple myeloma: current and future status.
- A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
- Therapy of relapsed and refractory multiple myeloma.
- Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices